United States & Mass General Brigham Cancer Institute
3 shared events · Importance 3 · Last updated Aug 22, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
United States: The study population is U.S.-based, and findings may influence public health recommendations.
Mass General Brigham Cancer Institute: Conducted and published the study, enhancing its reputation in cancer research.
Aug 17, 2026 · 20 articles
Business
United States: Regulatory jurisdiction for potential approval of engasertib; the financing supports U.S. regulatory submissions.
Mass General Brigham Cancer Institute: Affiliation of the Principal Investigator, supporting the trial's clinical oversight.
Aug 11, 2026 · 8 articles
Tech
United States: The US is the primary market for the treatment, with regulatory approval and healthcare system implications.
Mass General Brigham Cancer Institute: Experts from the institute commented on the significance of the trial and its potential to change treatment paradigms.
Aug 19, 2026 · 108 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and Mass General Brigham Cancer Institute interact across events, view sentiment trends, and discover connected entities.
Open Dashboard